Co-enzyme Q10 and idebenone use in Friedreich's ataxia

98Citations
Citations of this article
122Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Friedreich's ataxia is a debilitating progressive neurodegenerative disease associated with cardiomyopathy and other features. The underlying cause is a deficiency of the mitochondrial protein frataxin which causes mitochondrial iron deposition, increased oxidative stress and impaired adenosine triphosphate production. Over the last 15 years, multiple clinical trials have assessed the efficacy of antioxidant agents in this disease. This article reviews trials of the two most important agents, namely co-enzyme Q10 and idebenone. © 2013 International Society for Neurochemistry.

Cite

CITATION STYLE

APA

Parkinson, M. H., Schulz, J. B., & Giunti, P. (2013, August). Co-enzyme Q10 and idebenone use in Friedreich’s ataxia. Journal of Neurochemistry. https://doi.org/10.1111/jnc.12322

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free